Avinger (NASDAQ:AVGR) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Tuesday. The firm presently has a $0.25 price target on the medical device company’s stock. Zacks Investment Research‘s price target indicates a potential downside of 10.71% from the company’s previous close.

According to Zacks, “Avinger, Inc. is engaged in designing, manufacturing and selling image-guided, catheter-based systems to treat peripheral arterial disease. The company’s product consists of Lightbox imaging console, Wildcat, Kittycat, Ocelot, Ocelot PIXL, Ocelot MVRX and Juicebox. Avinger, Inc. is based in Redwood City, California. “

AVGR opened at $0.28 on Tuesday. The stock has a market capitalization of $3.47 million, a PE ratio of 0.00 and a beta of 1.99. Avinger has a 1 year low of $0.27 and a 1 year high of $11.96.

Avinger (NASDAQ:AVGR) last posted its quarterly earnings results on Tuesday, November 13th. The medical device company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.05). The firm had revenue of $2.02 million during the quarter. As a group, research analysts expect that Avinger will post -7.19 earnings per share for the current year.

Avinger Company Profile

Avinger, Inc, a commercial-stage medical device company, designs, manufactures, and sells image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease (PAD) in the United States and Europe. It develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures.

Recommended Story: Quiet Period

Get a free copy of the Zacks research report on Avinger (AVGR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Avinger Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avinger and related companies with MarketBeat.com's FREE daily email newsletter.